[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564203":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":57,"collaborators":62,"id":64,"slug":24,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":24,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":89,"whyStopped":24,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University Medical Center Ho Chi Minh City (UMC)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LDL-C guided-LLT","ACTIVE_COMPARATOR","Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.",[13],"Other: LDL-C-guided-LLT",{"label":15,"type":16,"description":17,"interventionNames":18},"ApoB-guided-LLT","EXPERIMENTAL","Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets.",[19],"Other: ApoB-guided-LLT",[21,25],{"type":6,"name":15,"description":22,"armGroupLabels":23,"otherNames":24},"Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets",[15],null,{"type":6,"name":26,"description":11,"armGroupLabels":27,"otherNames":24},"LDL-C-guided-LLT",[9],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Vu Hoang Vu, Ph.D M.D","CONTACT","+84908431304","vu.vh@umc.edu.vn",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Bao Thien Duong, M.D","+84936287137","bao.dt1@umc.edu.vn",[39],{"facility":40,"status":24,"city":41,"state":24,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University Medical Center Ho Chi Minh City","Ho Chi Minh City","700000","Vietnam","VN",{"type":46,"coordinates":47},"Point",[48,49],106.62965,10.82302,{"lat":49,"lon":48},[52,54,56],{"name":30,"role":31,"phone":53,"phoneExt":24,"email":33},"+84‭908431304‬",{"name":35,"role":31,"phone":55,"phoneExt":24,"email":37},"+84‭936287137",{"name":30,"role":31,"phone":24,"phoneExt":24,"email":24},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":61,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Vu Hoang Vu","Head of Interventional Cardiology Department, PhD MD","University of Medicine and Pharmacy at Ho Chi Minh City",[63],{"name":61,"class":6},"100564203",false,"NCT06626126","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial","ApoB-guidedLLT","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n3. Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n3. Liver Disease: patients with cirrhosis or significant liver dysfunction.\n4. Patients with contraindication to statin or other lipid-lowering therapy.\n5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).","ALL","18 Years",{"count":74,"type":75},1448,"ESTIMATED","INTERVENTIONAL",[78],"NA","This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.",[81,82,83,84],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention","LDL-cholesterol","Lipid Metabolism Disorders",[69,86,87,88],"PCI","Coronary artery disease","lipid lowering therapy","NOT_YET_RECRUITING","2024-10-13",{"date":92,"type":93},"2024-10-16","ACTUAL",{"date":95,"type":75},"2025-01-01",{"date":97,"type":75},"2029-01-01",{"name":5,"class":6},1]